Holen Sie sich die Stockscreener-App
342.57
1.54%
-5.37
Handel nachbörslich:
342.06
-0.51
-0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$347.94
Offen:
$345.45
24-Stunden-Volumen:
2.13M
Relative Volume:
0.78
Marktkapitalisierung:
$184.67B
Einnahmen:
$36.74B
Nettoeinkommen (Verlust:
$7.71B
KGV:
24.07
EPS:
14.2333
Netto-Cashflow:
$8.10B
1W Leistung:
-1.84%
1M Leistung:
-7.30%
6M Leistung:
+16.47%
1J Leistung:
+16.37%
1-Tages-Spanne:
$340.64
$348.17
1-Wochen-Bereich:
$340.64
$357.00
52-Wochen-Spanne:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
342.57 | 187.56B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
Under-the-skin Tepezza comparable to infused version in key study, Amgen says - BioPharma Dive
Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version - Citeline News & Insights
William Blair Maintains Amgen(AMGN.US) With Buy Rating - Moomoo
Amgen (AMGN) Reports Positive Phase 3 Results for Tepezza in Thy - GuruFocus
Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS) - The Globe and Mail
Why Is Viridian Therapeutics Stock Sinking Monday? - Benzinga
William Blair reiterates Amgen stock rating on positive Tepezza data - Investing.com
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
Amgen (AMGN) Achieves Impressive Phase 3 Results with Tepezza - GuruFocus
Amgen Posts 77% Response In Thyroid Eye Disease Study - Benzinga
Amgen (AMGN) Reveals Positive Phase 3 Results for Subcutaneous T - GuruFocus
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease - fiercepharma.com
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks - AD HOC NEWS
Buffalo Business & Estate Services Ltd. Takes Position in Amgen Inc. $AMGN - marketbeat.com
BXM Wealth LLC Increases Stock Position in Amgen Inc. $AMGN - marketbeat.com
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34 - TradingView
Amgen Inc. $AMGN Position Boosted by JB Capital LLC - marketbeat.com
A Look At Amgen (AMGN) Valuation After New Repatha Data And Zai Lab Oncology Collaboration - simplywall.st
Amgen Inc. (AMGN) stock price, news, quote and history - Yahoo Finance UK
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN - marketbeat.com
SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN - marketbeat.com
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - IndexBox
Amgen Beats Estimates by $400 Million in Q4: Here’s Why Analysts Target $350 - TIKR.com
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study - TipRanks
Dorato Capital Management Invests $1.58 Million in Amgen Inc. $AMGN - marketbeat.com
Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN - marketbeat.com
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile - Yahoo Finance
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Australia
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
Amgen's Diversification Continues To Pay Off, RBC Says - Moomoo
Turning Up the Volume on IgG4-RD Awareness and Diagnosis - Amgen
Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next - tipranks.com
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? - Insider Monkey
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $390 - Moomoo
HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN - marketbeat.com
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: ReportAmgen (NASDAQ:AM - Benzinga
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy - AASTOCKS.com
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative? - simplywall.st
AMGEN INC (AMGNCL.SN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Amgen Inc. Stock: Biotech Leader's Strategic Pipeline and Oncology Focus Drive Long-Term Investor Va - AD HOC NEWS
Zai Lab gains after Amgen clinical trial deal (ZLAB:NASDAQ) - Seeking Alpha
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen (AMGN) and Zai Lab Partner for Lung Cancer Treatment Study - gurufocus.com
Once the center of a $3.7 billion buyout, drug blamed for eight deaths draws FDA alert - The Business Journals
Zai Lab Limited and Amgen Inc Enter Global Clinical Trial Collaboration Agreement - marketscreener.com
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):